TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27

American Journal of Physiology - Endocrinology and Metabolism

Volumn 281, Issue 2 44-2, 2001, Pages

  Hupfeld, Christopher J ^a   Weiss, Robert H ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

Atherosclerosis; Cell cycle; Diabetes; Peroxisome proliferator activated receptor ; Proliferation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTISENSE OLIGONUCLEOTIDE; CIGLITAZONE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN P21; PROTEIN P27;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

EID: 0034880615     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.2001.281.2.e207     Document Type: Article

References (47)

1. Peroxisome proliferator-activated receptor gamma1 expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation
2. PPARgamma: The ultimate thrifty gene
3. Peroxisome proliferator-activated receptor (PPAR) gamma in human vascular smooth muscle cells: Inhibition of growth, migration, and c-fos expression by the PPARγ activator troglitazone
4. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta-12,14 prostaglandin J2
5. Non-apoptotic growth arrest associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand 15-deoxy-delta12,14 prostaglandin J2
6. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer
7. The p21cip1 and p27kip1 CDK "inhibitors" are essential activators of cyclin D-dependent kinases in murine fibroblasts
8. Activation of peroxisome proliferator-activated receptors alpha and gamma induces apoptosis in human monocyte-derived macrophages
9. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle
10. Antiproliferative effects of PCA-4230, a new antithrombotic drug, in vascular smooth muscle cells
11. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
12. Regulation of the G1 phase of the mammalian cell cycle
13. Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells
14. Effects of troglitazone and pioglitazone on cytokine-mediated endothelial cell proliferation in vitro
15. Expression of peroxisome proliferator-activated receptor gamma (PPARγ) in human transitional bladder cancer and its role in inducing cell death
16. How to improve the cardiac prognosis for diabetes
17. The interaction of RB with E2F coincides with inhibition of the transcriptional activity of E2F
18. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
19. Direct binding of cyclin D to the retinoblastoma gene product (pRB) and pRB phosphorylation by the cyclin D-dependent kinase CDK4
20. Angiotensin II regulates the cell cycle in vascular smooth muscle cells from SHR
21. Expression and function of PPAR gamma in rat and human vascular smooth muscle cells
22. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
23. Expression of macrophage (Mphi) scavenger receptor, CD36, in cultured human aortic smooth muscle cells in association with expression of peroxisome proliferator-activated receptor gamma, which regulates gain of Mphi-like phenotype in vitro, and its implication in atherogenesis
24. Differential expression of the cyclin kinase inhibitor p27 in primary hepatocytes in early-mid G1 and G1/S transitions
25. Effects of thiazolidenediones on growth and differentiation of human aorta and coronary myocytes
26. Role of PPARγ in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis
27. Terminal differentiation of human breast cancer through PPAR gamma
28. Peroxisomal proliferator-activated receptor gamma ligands inhibit choroidal neovascularization
29. Human arterial smooth muscle cell proliferation in diabetes
30. Competence effect of PDGF on Ki-67 antigen and DNA contents, and its inhibition by trichostatin-A and a butylydine phalide BP-421 in primary smooth muscle cells of rat aorta by flow cytometry
31. Troglitazone induces apoptosis via the p53 and GADD45 pathway in vascular smooth muscle cells
32. PPARgamma and the treatment of insulin resistance
33. PPARgamma-mediated regulation of normal and malignant B lineage cells
34. Acceleration of G1/S phase transition by expression of cyclins D1 and E with an inducible system
35. Atherosclerosis - An inflammatory disease
36. Mammalian G1 cyclins
37. The Pezcoller Lecture: Cancer cell cycles revisited
38. Inhibitors of mammalian G1 cyclin-dependent kinases
39. Activation of human aortic smooth muscle cells is inhibited by PPARalpha but not by PPARgamma activators
40. mPPARγ2: Tissue specific regulator of an adipocyte enhancer
41. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid activated transcription factor
42. Inhibition of human lung cancer growth by the peroxisome proliferator-activated receptor agonists through induction of apoptosis
43. Peroxisome proliferator-activated receptor γ ligands inhibit retinoblastoma phosphorylation and G1-S transition in vascular smooth muscle cells
44. P21waf1/cip1 is an assembly factor required for platelet-derived growth factor-induced vascular smooth muscle cell proliferation
45. Inhibition of tyrosine phosphorylation prevents thrombin-induced mitogenesis, but not intracellular free calcium release, in vascular smooth muscle cells
46. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo
47. Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells